Buy Glenmark Pharmaceuticals, target price Rs 1,779: Choice Equity Broking

 21 Nov 2024 09:11 AM

Choice Equity Broking has issued a buy call for Glenmark Pharmaceuticals, setting a target price of Rs 1,779. The brokerage projects robust growth for the pharmaceutical company, fueled by new product launches and expanding margins. They anticipate a 14.8% revenue CAGR and a 44.7% EBITDA CAGR from FY24-27E. Glenmark recently reported a consolidated total income of Rs 3473.

Glenmark to focus on becoming branded company, says Glenn Saldanha

 19 Nov 2024 04:57 PM

Glenmark Pharmaceuticals, having navigated recent challenges, is shifting its focus to branded products for higher profit margins. The company, aiming for a 12%-15% growth rate, divested its active pharmaceutical ingredient business to concentrate on branded pharmaceuticals, particularly in respiratory, dermatology, and oncology.

GLENMARK PHARMA: CO CFO SAYS CO TO LAUNCH THE RESPIRATORY DRUG IN NEXT 6-8 MONTHS IN US - CNBCTV18

 18 Nov 2024 10:41 AM

GLENMARK PHARMA: CO CFO SAYS CO TO LAUNCH THE RESPIRATORY DRUG IN NEXT 6-8 MONTHS IN US - CNBCTV18

GLENMARK PHARMA: CO CFO SAYS H2 MARGINS IS EXPECTED TO BE BETTER GIVEN THE RESPIRATORY LAUNCHES- CNBCTV1

 18 Nov 2024 10:39 AM

GLENMARK PHARMA: CO CFO SAYS H2 MARGINS IS EXPECTED TO BE BETTER GIVEN THE RESPIRATORY LAUNCHES- CNBCTV1

Glenmark Pharma Q2 Results: Co posts Rs 355 crore net profit on robust sales growth

 14 Nov 2024 08:41 PM

Glenmark Pharma reported Rs 340 crore net profit in Q2FY25 led by robust sales growth in India and Europe. The drugmaker reported a net loss of Rs 180 crore in the corresponding quarter of the previous year.

GLENMARK : ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCES FIRST PRESENTATION OF DATA FROM PHASE 1 STUDY OF THE TRISPECIFIC ISB 2001 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/RMM) AT UPCOMING ASH ANNUAL MEETING

 06 Nov 2024 09:32 AM

GLENMARK : ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCES FIRST PRESENTATION OF DATA FROM PHASE 1 STUDY OF THE TRISPECIFIC ISB 2001 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/RMM) AT UPCOMING ASH ANNUAL MEETING

GLENMARK LIFESCIENCES: DOUBLE UPGRADE BY KOTAK ON GLENMARK LIFE SCIENCES|| UPGRADE FROM REDUCE TO BUY|| 2QFY25 DENTED BY TEMPORARY CLOSURE IN ANKLESHWAR CURATED API PORTFOLIO &WITH RICH PIPELINE & CDMO CLIENT WINS TO DRIVE GROWTH

 28 Oct 2024 11:14 AM

GLENMARK LIFESCIENCES: DOUBLE UPGRADE BY KOTAK ON GLENMARK LIFE SCIENCES|| UPGRADE FROM REDUCE TO BUY|| 2QFY25 DENTED BY TEMPORARY CLOSURE IN ANKLESHWAR CURATED API PORTFOLIO &WITH RICH PIPELINE & CDMO CLIENT WINS TO DRIVE GROWTH

GLENMARK LIFE SCIENCES: Q2 EBITDA 1.3B RUPEES VS 1.7B (YOY) || Q2 EBITDA MARGIN 26.51% VS 28.06% (YOY)

 24 Oct 2024 06:56 PM

GLENMARK LIFE SCIENCES: Q2 EBITDA 1.3B RUPEES VS 1.7B (YOY) || Q2 EBITDA MARGIN 26.51% VS 28.06% (YOY)

GLENMARK LIFE SCIENCES: Q2 REVENUE 5.1B RUPEES VS 6B (YOY)

 24 Oct 2024 06:56 PM

GLENMARK LIFE SCIENCES: Q2 REVENUE 5.1B RUPEES VS 6B (YOY)

GLENMARK LIFE SCIENCES: Q2 SL NET PROFIT 953M RUPEES VS 1.2B (YOY); 1.1B (QOQ)

 24 Oct 2024 06:56 PM

GLENMARK LIFE SCIENCES: Q2 SL NET PROFIT 953M RUPEES VS 1.2B (YOY); 1.1B (QOQ)